{
    "hands_on_practices": [
        {
            "introduction": "Effective asthma therapy often involves blocking pathways that cause bronchoconstriction. This practice delves into the fundamental principles of competitive antagonism, a key mechanism for muscarinic antagonists like ipratropium. By applying the classic Schild analysis to a hypothetical dataset , you will learn to quantify a drug's receptor affinity ($K_{B}$) from its effect on an agonist's dose-response curve, bridging the gap between experimental data and a core pharmacodynamic parameter.",
            "id": "4975894",
            "problem": "An isolated human bronchial smooth muscle preparation is used to examine competitive antagonism relevant to asthma pharmacotherapy. Acetylcholine (agonist) evokes bronchoconstriction via muscarinic type $3$ receptors. Ipratropium (antagonist), a short-acting muscarinic antagonist used in asthma, is applied at fixed bath concentrations. Assume the following well-tested foundational facts: receptor binding at equilibrium follows the law of mass action, competitive antagonists bind reversibly to the same receptor site as the agonist, and for a purely competitive antagonist the maximal agonist effect is unchanged while the agonist concentrationâ€“response curve is shifted rightward.\n\nIn this preparation, the acetylcholine half-maximal effective concentration (median effective concentration) in the absence of antagonist is measured as $2.00\\,\\mu\\text{M}$. In the presence of three fixed bath concentrations of ipratropium, the following median effective concentrations for acetylcholine are obtained:\n- At $0.50\\,\\text{nM}$ ipratropium, the acetylcholine median effective concentration is $2.50\\,\\mu\\text{M}$.\n- At $2.00\\,\\text{nM}$ ipratropium, the acetylcholine median effective concentration is $4.00\\,\\mu\\text{M}$.\n- At $8.00\\,\\text{nM}$ ipratropium, the acetylcholine median effective concentration is $10.0\\,\\mu\\text{M}$.\n\nAll three antagonist conditions show the same maximal effect as control. Starting from the equilibrium binding framework for competitive antagonism and using the concept of dose ratio derived from receptor theory, construct a Schild analysis by relating the rightward shifts to antagonist concentrations. Use the analysis to estimate the equilibrium dissociation constant of ipratropium for the receptor, $K_{B}$. Express your final estimate of $K_{B}$ in $\\text{nM}$ and round your answer to three significant figures. The final answer must be a single real-valued number with no units in the box.",
            "solution": "The problem statement is evaluated to be scientifically grounded, well-posed, objective, and internally consistent. It describes a classic pharmacological experiment for characterizing a competitive antagonist, using established principles and standard methodology. All provided data are necessary and sufficient for a solution.\n\nThe core of this problem lies in the application of the Gaddum-Schild equation, which describes the relationship between the concentration of a competitive antagonist and the degree of rightward shift it causes in the agonist's concentration-response curve.\n\nLet $[A]$ represent the concentration of the agonist, acetylcholine, and $[I]$ represent the concentration of the antagonist, ipratropium. The median effective concentration, $EC_{50}$, is the concentration of agonist required to produce $50\\%$ of the maximal response. The problem provides the control $EC_{50}$ for acetylcholine in the absence of ipratropium as $EC_{50, \\text{control}} = 2.00\\,\\mu\\text{M}$. In the presence of a fixed concentration of antagonist $[I]$, a new, higher agonist concentration, which we denote as $EC'_{50}$, is required to achieve the same $50\\%$ response.\n\nThe dose ratio, $DR$, is a fundamental concept in this analysis. It is defined as the ratio of the agonist concentration required to produce a given effect in the presence of the antagonist to the concentration required for the same effect in the absence of the antagonist. In this case, we use the ratio of the median effective concentrations:\n$$\nDR = \\frac{EC'_{50}}{EC_{50, \\text{control}}}\n$$\n\nFor a simple, reversible competitive antagonist, the dose ratio is related to the antagonist concentration $[I]$ and its equilibrium dissociation constant, $K_B$, by the Gaddum-Schild equation:\n$$\nDR = 1 + \\frac{[I]}{K_B}\n$$\nThe constant $K_B$ represents the concentration of antagonist at which half of the receptors would be occupied by the antagonist at equilibrium. A lower $K_B$ signifies a higher affinity of the antagonist for the receptor.\n\nThis equation can be rearranged to solve for $K_B$:\n$$\nDR - 1 = \\frac{[I]}{K_B} \\implies K_B = \\frac{[I]}{DR - 1}\n$$\nWe can use the provided experimental data to calculate $K_B$ for each concentration of ipratropium. The units of $EC_{50}$ and $EC'_{50}$ are both $\\mu\\text{M}$, so they cancel when calculating the dimensionless dose ratio. The resulting units for $K_B$ will be the same as the units used for the antagonist concentration $[I]$, which is $\\text{nM}$.\n\nLet us analyze each data point.\n\n**Data Point 1:**\nAntagonist concentration: $[I_1] = 0.50\\,\\text{nM}$.\nNew median effective concentration: $EC'_{50,1} = 2.50\\,\\mu\\text{M}$.\nThe dose ratio is:\n$$\nDR_1 = \\frac{2.50\\,\\mu\\text{M}}{2.00\\,\\mu\\text{M}} = 1.25\n$$\nNow, we calculate $K_B$ using this data point:\n$$\nK_{B,1} = \\frac{[I_1]}{DR_1 - 1} = \\frac{0.50\\,\\text{nM}}{1.25 - 1} = \\frac{0.50\\,\\text{nM}}{0.25} = 2.00\\,\\text{nM}\n$$\n\n**Data Point 2:**\nAntagonist concentration: $[I_2] = 2.00\\,\\text{nM}$.\nNew median effective concentration: $EC'_{50,2} = 4.00\\,\\mu\\text{M}$.\nThe dose ratio is:\n$$\nDR_2 = \\frac{4.00\\,\\mu\\text{M}}{2.00\\,\\mu\\text{M}} = 2.00\n$$\nCalculating $K_B$:\n$$\nK_{B,2} = \\frac{[I_2]}{DR_2 - 1} = \\frac{2.00\\,\\text{nM}}{2.00 - 1} = \\frac{2.00\\,\\text{nM}}{1} = 2.00\\,\\text{nM}\n$$\nNote that for this case, $DR=2$. By definition, the antagonist concentration that produces a dose ratio of $2$ is equal to its $K_B$. The data point directly gives $K_B=2.00\\,\\text{nM}$.\n\n**Data Point 3:**\nAntagonist concentration: $[I_3] = 8.00\\,\\text{nM}$.\nNew median effective concentration: $EC'_{50,3} = 10.0\\,\\mu\\text{M}$.\nThe dose ratio is:\n$$\nDR_3 = \\frac{10.0\\,\\mu\\text{M}}{2.00\\,\\mu\\text{M}} = 5.00\n$$\nCalculating $K_B$:\n$$\nK_{B,3} = \\frac{[I_3]}{DR_3 - 1} = \\frac{8.00\\,\\text{nM}}{5.00 - 1} = \\frac{8.00\\,\\text{nM}}{4} = 2.00\\,\\text{nM}\n$$\n\nAll three experimental conditions yield an identical value for $K_B$ of $2.00\\,\\text{nM}$. This indicates that the provided data perfectly conform to the model of simple competitive antagonism. In a real experiment, one would typically use a linear regression on a Schild plot ($\\log_{10}(DR-1)$ versus $\\log_{10}[I]$) to find the best estimate of $K_B$ from noisy data. However, given the perfect consistency of these results, such a procedure is unnecessary. The slope of such a plot would be exactly $1$, confirming a simple competitive mechanism, and the x-intercept would be $\\log_{10}(K_B)$.\n\nThe consistent result from all three conditions provides a highly confident estimate for the equilibrium dissociation constant. The estimated value for $K_B$ is $2.00\\,\\text{nM}$. The problem requires the answer to be rounded to three significant figures, which the value $2.00$ already satisfies.",
            "answer": "$$\n\\boxed{2.00}\n$$"
        },
        {
            "introduction": "For inhaled medications, how the drug is delivered is as important as the drug itself. This exercise explores the biopharmaceutics of aerosol therapy by modeling the impact of a spacer device on the delivery of an inhaled corticosteroid . You will calculate how a spacer improves the therapeutic window by simultaneously increasing the fraction of the drug reaching the lungs and decreasing the amount deposited in the mouth and throat, which helps minimize systemic side effects.",
            "id": "4975886",
            "problem": "An adult with moderate persistent asthma uses a pressurized metered-dose inhaler (pMDI) containing the inhaled corticosteroid (ICS) fluticasone propionate. You are asked to quantify how adding a valved holding chamber (spacer) changes oropharyngeal deposition and the fine particle fraction, and to predict the impact on systemic ICS exposure, using a simple, standard deposition and absorption framework grounded in mass balance and bioavailability.\n\nUse the following fundamental bases:\n- Emitted aerosol dose per actuation is $D$.\n- The fine particle fraction (FPF) is the fraction of emitted mass small enough to reach the lower airways; denote it by $\\mathrm{FPF}$.\n- Among fine particles, a fraction $k_{l}$ deposits in the lung, so the lung deposition fraction is $L = k_{l}\\,\\mathrm{FPF}$.\n- Among non-fine particles (fraction $1 - \\mathrm{FPF}$), a fraction $k_{o}$ impacts in the oropharynx, so the oropharyngeal deposition fraction is $O = k_{o}\\,(1 - \\mathrm{FPF})$. Assume oropharyngeal deposition is cleared and swallowed.\n- Systemic exposure per actuation, $E$, is the sum of drug absorbed from the lungs and from the gastrointestinal tract after swallowing, where $f_{p}$ is the pulmonary absorption fraction of lung-deposited drug entering the systemic circulation, and $f_{o}$ is the oral bioavailability of swallowed drug entering the systemic circulation.\n\nConsider two conditions: without spacer and with spacer. Take the following parameter values that are consistent with device performance and pharmacokinetics of fluticasone propionate:\n- Emitted dose per actuation: $D = 200$ micrograms.\n- Pulmonary absorption fraction: $f_{p} = 0.90$.\n- Oral bioavailability: $f_{o} = 0.01$.\n- Without spacer: $\\mathrm{FPF}_{0} = 0.30$, $k_{l,0} = 0.70$, $k_{o,0} = 0.90$.\n- With spacer: $\\mathrm{FPF}_{1} = 0.50$, $k_{l,1} = 0.80$, $k_{o,1} = 0.50$.\n\nCompute the following three quantities:\n1. The fractional change in oropharyngeal deposition, $\\Delta O = \\dfrac{O_{1} - O_{0}}{O_{0}}$, where $O_{0}$ and $O_{1}$ are the oropharyngeal deposition fractions without and with spacer, respectively.\n2. The fractional change in fine particle fraction, $\\Delta \\mathrm{FPF} = \\dfrac{\\mathrm{FPF}_{1} - \\mathrm{FPF}_{0}}{\\mathrm{FPF}_{0}}$.\n3. The ratio of systemic exposures per actuation, $R = \\dfrac{E_{1}}{E_{0}}$, where $E_{0}$ and $E_{1}$ are the systemic exposures without and with spacer, respectively.\n\nExpress all three results as pure decimal numbers with no units. Round each to four significant figures. Report your final answer as a single row matrix containing, in order, $\\Delta O$, $\\Delta \\mathrm{FPF}$, and $R$.",
            "solution": "The problem statement is first subjected to a validation process.\n\n### Step 1: Extract Givens\nThe verbatim data, variables, and definitions provided in the problem statement are:\n- Emitted aerosol dose per actuation: $D$\n- Fine particle fraction: $\\mathrm{FPF}$\n- Lung deposition fraction: $L = k_{l}\\,\\mathrm{FPF}$\n- Oropharyngeal deposition fraction: $O = k_{o}\\,(1 - \\mathrm{FPF})$\n- Systemic exposure per actuation: $E$, sum of drug absorbed from lungs and gastrointestinal tract.\n- Pulmonary absorption fraction of lung-deposited drug: $f_{p}$\n- Oral bioavailability of swallowed drug: $f_{o}$\n- Emitted dose per actuation: $D = 200$ micrograms\n- Pulmonary absorption fraction: $f_{p} = 0.90$\n- Oral bioavailability: $f_{o} = 0.01$\n- Without spacer (subscript 0): $\\mathrm{FPF}_{0} = 0.30$, $k_{l,0} = 0.70$, $k_{o,0} = 0.90$\n- With spacer (subscript 1): $\\mathrm{FPF}_{1} = 0.50$, $k_{l,1} = 0.80$, $k_{o,1} = 0.50$\n- Quantity 1 to compute: Fractional change in oropharyngeal deposition, $\\Delta O = \\dfrac{O_{1} - O_{0}}{O_{0}}$\n- Quantity 2 to compute: Fractional change in fine particle fraction, $\\Delta \\mathrm{FPF} = \\dfrac{\\mathrm{FPF}_{1} - \\mathrm{FPF}_{0}}{\\mathrm{FPF}_{0}}$\n- Quantity 3 to compute: Ratio of systemic exposures, $R = \\dfrac{E_{1}}{E_{0}}$\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the validation criteria.\n- **Scientifically Grounded**: The problem presents a standard, simplified compartmental model for the pharmacokinetics of an inhaled drug. The concepts of fine particle fraction ($\\mathrm{FPF}$), oropharyngeal versus lung deposition, and bioavailability ($f_p$, $f_o$) are fundamental principles in aerosol science and pharmacology. The parameter values given for fluticasone propionate (high pulmonary absorption, very low oral bioavailability) and for the effect of a spacer (increasing $\\mathrm{FPF}$, decreasing oropharyngeal deposition) are consistent with established scientific literature. The model is a valid simplification for educational and analytical purposes.\n- **Well-Posed**: All variables are clearly defined, and all necessary numerical values are provided to compute the requested quantities. The problem is self-contained and leads to a unique solution.\n- **Objective**: The problem is stated using precise, quantitative language, free of ambiguity or subjective claims.\n\nThe problem does not violate any of the invalidity criteria. It is scientifically sound, formalizable, complete, realistic, and well-posed.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A full solution will be provided.\n\nThe solution proceeds by first calculating the necessary quantities for the two specified conditions (without and with a spacer) and then computing the requested final values.\n\nFirst, we formalize the expression for systemic exposure, $E$. The total mass of drug absorbed into the systemic circulation is the sum of the mass absorbed from the lungs and the mass absorbed from the gastrointestinal tract after swallowing the oropharyngeally deposited drug.\nThe mass deposited in the lungs is $D \\cdot L = D \\cdot k_{l} \\cdot \\mathrm{FPF}$.\nThe mass deposited in the oropharynx is $D \\cdot O = D \\cdot k_{o} \\cdot (1 - \\mathrm{FPF})$.\nSystemic exposure is thus given by:\n$$E = f_{p} \\cdot (D \\cdot L) + f_{o} \\cdot (D \\cdot O)$$\n$$E = D (f_{p} L + f_{o} O)$$\nSubstituting the definitions for $L$ and $O$:\n$$E = D \\left(f_{p} k_{l} \\mathrm{FPF} + f_{o} k_{o} (1 - \\mathrm{FPF})\\right)$$\n\nNext, we calculate the deposition fractions for each condition.\n\n**Condition 0: Without Spacer**\nThe parameters are $\\mathrm{FPF}_{0} = 0.30$, $k_{l,0} = 0.70$, and $k_{o,0} = 0.90$.\nThe oropharyngeal deposition fraction $O_{0}$ is:\n$$O_{0} = k_{o,0}(1 - \\mathrm{FPF}_{0}) = 0.90 \\times (1 - 0.30) = 0.90 \\times 0.70 = 0.63$$\nThe lung deposition fraction $L_{0}$ is:\n$$L_{0} = k_{l,0} \\mathrm{FPF}_{0} = 0.70 \\times 0.30 = 0.21$$\n\n**Condition 1: With Spacer**\nThe parameters are $\\mathrm{FPF}_{1} = 0.50$, $k_{l,1} = 0.80$, and $k_{o,1} = 0.50$.\nThe oropharyngeal deposition fraction $O_{1}$ is:\n$$O_{1} = k_{o,1}(1 - \\mathrm{FPF}_{1}) = 0.50 \\times (1 - 0.50) = 0.50 \\times 0.50 = 0.25$$\nThe lung deposition fraction $L_{1}$ is:\n$$L_{1} = k_{l,1} \\mathrm{FPF}_{1} = 0.80 \\times 0.50 = 0.40$$\n\nNow we can compute the three required quantities.\n\n**1. Fractional change in oropharyngeal deposition, $\\Delta O$**\nThis is defined as $\\Delta O = \\dfrac{O_{1} - O_{0}}{O_{0}}$. Using the calculated values:\n$$\\Delta O = \\frac{0.25 - 0.63}{0.63} = \\frac{-0.38}{0.63} \\approx -0.6031746...$$\nRounding to four significant figures gives:\n$$\\Delta O \\approx -0.6032$$\n\n**2. Fractional change in fine particle fraction, $\\Delta \\mathrm{FPF}$**\nThis is defined as $\\Delta \\mathrm{FPF} = \\dfrac{\\mathrm{FPF}_{1} - \\mathrm{FPF}_{0}}{\\mathrm{FPF}_{0}}$. Using the given values:\n$$\\Delta \\mathrm{FPF} = \\frac{0.50 - 0.30}{0.30} = \\frac{0.20}{0.30} = \\frac{2}{3} \\approx 0.666666...$$\nRounding to four significant figures gives:\n$$\\Delta \\mathrm{FPF} \\approx 0.6667$$\n\n**3. Ratio of systemic exposures, $R$**\nThis is defined as $R = \\dfrac{E_{1}}{E_{0}}$. Using the expression for $E$:\n$$R = \\frac{D (f_{p} L_{1} + f_{o} O_{1})}{D (f_{p} L_{0} + f_{o} O_{0})} = \\frac{f_{p} L_{1} + f_{o} O_{1}}{f_{p} L_{0} + f_{o} O_{0}}$$\nThe dose $D$ cancels out. We substitute the values for $f_{p}=0.90$, $f_{o}=0.01$, and the calculated deposition fractions:\n$$R = \\frac{(0.90)(0.40) + (0.01)(0.25)}{(0.90)(0.21) + (0.01)(0.63)}$$\nCalculate the numerator and denominator separately:\nNumerator $= 0.36 + 0.0025 = 0.3625$\nDenominator $= 0.189 + 0.0063 = 0.1953$\n$$R = \\frac{0.3625}{0.1953} \\approx 1.85611879...$$\nRounding to four significant figures gives:\n$$R \\approx 1.856$$\n\nThe three computed quantities, rounded to four significant figures, are $\\Delta O = -0.6032$, $\\Delta \\mathrm{FPF} = 0.6667$, and $R = 1.856$. These are to be reported in a single row matrix.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n-0.6032 & 0.6667 & 1.856\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Translating pharmacology theory into clinical practice culminates in designing a safe and effective regimen for an individual patient. This problem focuses on applying core pharmacokinetic principles to tailor the dosing of theophylline, a methylxanthine bronchodilator with a narrow therapeutic index . You will derive and use formulas for calculating loading and maintenance doses, integrating patient-specific factors such as smoking status to achieve a target steady-state drug concentration.",
            "id": "4975924",
            "problem": "An adult with moderate persistent asthma is to begin sustained-release theophylline therapy. Assume linear, one-compartment pharmacokinetics with first-order elimination and that steady state under multiple dosing satisfies mass balance. The patient weighs $70$ kilograms. The apparent volume of distribution per kilogram is $0.47$ liters per kilogram. The baseline total body clearance per kilogram for a non-smoker is $0.029$ liters per kilogram per hour. Due to current smoking, the patient's total body clearance is increased multiplicatively by a factor of $1.5$ relative to a non-smoker. The oral bioavailability is $0.90$. The dosing interval is $12$ hours. The therapeutic goal is an average steady-state plasma theophylline concentration of $10$ milligrams per liter.\n\nUsing only the definitions that clearance is the proportionality between elimination rate and concentration, that at steady state the average rate of drug input equals the average rate of drug elimination, and that the amount of drug in the body after distribution is the product of concentration and volume of distribution, derive from first principles the expressions needed to compute an oral loading dose to promptly attain the target concentration and an oral maintenance dose per dosing interval to maintain the target average steady-state concentration. Then calculate both doses numerically for this patient, incorporating the effect of smoking on clearance as specified.\n\nRound both doses to three significant figures. Express both doses in milligrams (mg). Report your final answer as two values: the loading dose and the maintenance dose per $12$ hours, in that order.",
            "solution": "The problem is valid as it is scientifically grounded, well-posed, and objective. It presents a standard clinical pharmacokinetics scenario with realistic parameters and a clear objective. We will proceed to derive the required expressions from the stated first principles and then calculate the numerical values for the loading and maintenance doses.\n\nThe provided first principles are:\n1.  The rate of drug elimination, $Rate_{out}$, is proportional to the plasma concentration, $C$:\n    $$Rate_{out} = CL \\times C$$\n    where $CL$ is the total body clearance.\n2.  At steady state, the average rate of drug input, $Rate_{in,avg}$, equals the average rate of drug elimination, $Rate_{out,avg}$:\n    $$Rate_{in,avg} = Rate_{out,avg}$$\n3.  The amount of drug in the body, $A$, is the product of the plasma concentration, $C$, and the apparent volume of distribution, $V_d$:\n    $$A = C \\times V_d$$\n\nLet the patient's weight be $W$, the apparent volume of distribution per kilogram be $V_{d,kg}$, the baseline clearance per kilogram for a non-smoker be $CL_{kg,ns}$, the multiplicative factor for smoking be $f_{smoking}$, the oral bioavailability be $F$, the dosing interval be $\\tau$, and the target average steady-state plasma concentration be $\\bar{C}_{ss}$.\n\n**Derivation of the Maintenance Dose ($MD$)**\n\nThe maintenance dose, $MD$, is administered every dosing interval, $\\tau$, to maintain the target average steady-state concentration, $\\bar{C}_{ss}$. The principle governing this is the mass balance at steady state, where the average rate of drug administration equals the average rate of drug elimination.\n\nThe average rate of elimination at steady state, $Rate_{out,avg}$, is given by the product of the total body clearance, $CL$, and the average steady-state concentration, $\\bar{C}_{ss}$:\n$$Rate_{out,avg} = CL \\times \\bar{C}_{ss}$$\n\nThe maintenance dose, $MD$, is given orally. The fraction of the dose that reaches systemic circulation is determined by the bioavailability, $F$. Thus, the amount of drug entering the circulation per dose is $F \\times MD$. This amount is administered over a dosing interval, $\\tau$. The average rate of drug input, $Rate_{in,avg}$, is this effective dose averaged over the dosing interval:\n$$Rate_{in,avg} = \\frac{F \\times MD}{\\tau}$$\n\nAt steady state, we equate the average rates of input and elimination:\n$$Rate_{in,avg} = Rate_{out,avg}$$\n$$\\frac{F \\times MD}{\\tau} = CL \\times \\bar{C}_{ss}$$\n\nSolving for the maintenance dose, $MD$, we obtain the expression:\n$$MD = \\frac{CL \\times \\bar{C}_{ss} \\times \\tau}{F}$$\n\n**Derivation of the Loading Dose ($LD$)**\n\nThe purpose of a loading dose, $LD$, is to rapidly achieve a target therapeutic concentration. The problem specifies the goal is to promptly attain the target concentration, which we take to be the target average steady-state concentration, $\\bar{C}_{ss}$. This requires filling the apparent volume of distribution, $V_d$, to achieve this concentration.\n\nUsing the third principle provided, the total amount of drug, $A_{target}$, that must be in the body to achieve the target concentration, $\\bar{C}_{ss}$, is:\n$$A_{target} = \\bar{C}_{ss} \\times V_d$$\n\nThis is the amount of drug that must be present in the systemic circulation. For an oral dose, the administered loading dose, $LD$, is subject to incomplete absorption, quantified by the bioavailability, $F$. The amount of drug that actually enters the circulation from the oral loading dose is $F \\times LD$. To achieve the target amount in the body, we must have:\n$$F \\times LD = A_{target}$$\n$$F \\times LD = \\bar{C}_{ss} \\times V_d$$\n\nSolving for the oral loading dose, $LD$, gives the expression:\n$$LD = \\frac{\\bar{C}_{ss} \\times V_d}{F}$$\n\n**Numerical Calculation for the Patient**\n\nFirst, we calculate the patient-specific pharmacokinetic parameters, $V_d$ and $CL$, using the given data:\n- Patient weight, $W = 70 \\text{ kg}$\n- Volume of distribution per kg, $V_{d,kg} = 0.47 \\text{ L/kg}$\n- Baseline clearance per kg (non-smoker), $CL_{kg,ns} = 0.029 \\text{ L/kg/hr}$\n- Smoking adjustment factor, $f_{smoking} = 1.5$\n- Bioavailability, $F = 0.90$\n- Dosing interval, $\\tau = 12 \\text{ hr}$\n- Target average steady-state concentration, $\\bar{C}_{ss} = 10 \\text{ mg/L}$\n\nThe patient's total apparent volume of distribution, $V_d$, is:\n$$V_d = V_{d,kg} \\times W = 0.47 \\frac{\\text{L}}{\\text{kg}} \\times 70 \\text{ kg} = 32.9 \\text{ L}$$\n\nThe patient's total body clearance, $CL$, must be adjusted for smoking. The baseline clearance for a $70 \\text{ kg}$ non-smoker would be $CL_{kg,ns} \\times W$. The actual clearance is this value multiplied by the smoking factor:\n$$CL = (CL_{kg,ns} \\times W) \\times f_{smoking} = \\left(0.029 \\frac{\\text{L}}{\\text{kg} \\cdot \\text{hr}} \\times 70 \\text{ kg}\\right) \\times 1.5$$\n$$CL = (2.03 \\frac{\\text{L}}{\\text{hr}}) \\times 1.5 = 3.045 \\frac{\\text{L}}{\\text{hr}}$$\n\nNow we can calculate the doses.\n\n**Calculation of the Maintenance Dose ($MD$):**\nUsing the derived formula and the calculated parameters:\n$$MD = \\frac{CL \\times \\bar{C}_{ss} \\times \\tau}{F} = \\frac{3.045 \\frac{\\text{L}}{\\text{hr}} \\times 10 \\frac{\\text{mg}}{\\text{L}} \\times 12 \\text{ hr}}{0.90}$$\n$$MD = \\frac{365.4 \\text{ mg}}{0.90} = 406 \\text{ mg}$$\nThis value is already at three significant figures. Thus, the maintenance dose per $12$ hours is $406 \\text{ mg}$.\n\n**Calculation of the Loading Dose ($LD$):**\nUsing the derived formula and the calculated parameters:\n$$LD = \\frac{\\bar{C}_{ss} \\times V_d}{F} = \\frac{10 \\frac{\\text{mg}}{\\text{L}} \\times 32.9 \\text{ L}}{0.90}$$\n$$LD = \\frac{329 \\text{ mg}}{0.90} \\approx 365.555... \\text{ mg}$$\nRounding this result to three significant figures gives:\n$$LD = 366 \\text{ mg}$$\n\nThe calculated doses are a loading dose of $366 \\text{ mg}$ and a maintenance dose of $406 \\text{ mg}$ every $12$ hours.",
            "answer": "$$\\boxed{\\begin{pmatrix} 366 & 406 \\end{pmatrix}}$$"
        }
    ]
}